Evidence map›Paper›PMID 30686271›Full record

ArticleIsrael journal of health policy research2019

Patient equity and respiratory syncytial virus Immunoprophylaxis.

H Cody Meissner

Abstract readComment
In one paragraph

Article in Israel journal of health policy research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Socioeconomic Impact of RSV Hospitalization.Infectious diseases and therapy · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

H Cody MeissnerTufts University School of Medicine, Boston, MA, 02111, USA. cmeissner@tuftsmedicalcenter.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An analysis of benefit and cost is critical for independent advisory groups that provide evidence-based recommendations. In many countries, the role of RSV immunoprophylaxis for infants at increased risk of hospitalization is controversial because of limited benefit and high cost. The report by Ginsberg and co-workers provides evidence, that in Israel, despite the potential benefit of palivizumab prophylaxis in reducing a small number of RSV hospitalizations but no evidence of long-term benefit, the cost is difficult to justify. Ideally, a safe and effective RSV vaccine or more effective and less expensive monoclonal antibody soon will become available.

Indexed as

Antiviral AgentsRespiratory Syncytial Virus InfectionsAntibodies, Monoclonal, HumanizedCost-Benefit AnalysisHumansInfantIsraelPalivizumabAntibodies, Monoclonal, HumanizedAntiviral AgentsPalivizumabBronchiolitisImmunoprophylaxisPalivizumabRespiratory syncytial virus

Identifiers

PMID30686271
PMCPMC6348622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.